THOUSAND OAKS, Calif.
Jan. 9, 2014
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that
Jonathan M. Peacock
, executive vice president and chief financial officer, is leaving Amgen to pursue broader career opportunities. Peacock will be stepping down from his role as CFO effective
Friday, Jan. 10, 2014
, and is expected to remain employed with the company until May to assist with the transition.
Michael A. Kelly
, an 11-year Amgen veteran, has been named acting CFO, reporting to
Robert A. Bradway
, chairman and chief executive officer.
"Since joining Amgen over three years ago, Jon has played an important role in developing and implementing the company's strategy for growth and in delivering value for shareholders," said Bradway. "We thank Jon for his many contributions and fully support his desire to pursue broader opportunities."
Since 2010, Amgen has expanded globally, strengthened its pipeline and returned substantial capital to shareholders through buy-backs and dividends. Amgen's near and long-term outlook is strong with multiple levers for future growth including a robust pipeline, entry into biosimilars and international expansion.
In his role as acting CFO, Kelly will be responsible for the company's finance and investor relations operations. Since joining Amgen in 2003, he has served in a number of executive finance assignments, including five years as chief accounting officer and more recently as CFO for international commercial operations. Prior to joining Amgen, Kelly had finance roles at Tanox, Biogen and Monsanto Life Sciences.
is an experienced financial executive," said Bradway. "I am delighted to have him reporting to me as acting CFO while we search for Jon's successor."
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.